Apellis Pharmaceuticals, Inc. Stock News

Apellis Pharmaceuticals, Inc. ( APLS ) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President of Commercial Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Researc...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET.

Apellis Pharmaceuticals, Inc. ( APLS ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Eva Stroynowski Cedric Francois - Co-Founder, President, CEO & Director David Acheson - Executive Vice President of Commercial Caroline Baumal - Chief Medical Officer Timothy Sullivan - CFO & Treasurer Conference Call Participants Jonathan Miller - Evercore ISI Institutional Equities, ...

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare a...

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.m. ET.

Apellis Pharmaceuticals maintains a strong "Buy" rating for me, driven by robust SYFOVRE sales and recent EMPAVELI FDA approvals for rare kidney diseases. APLS is expanding SYFOVRE's potential with a phase 2 study combining it with siRNA APLS-3007, aiming to enhance efficacy in geographic atrophy. Upcoming phase 3 trials for EMPAVELI in FSGS and DGF represent significant pipeline catalysts, wit...